Skip to main content

Day: August 12, 2022

Marathon Gold Announces 2022 Second Quarter Results

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) today announces its financial results for the second quarter ending June 30, 2022 and provides an update on the Company’s activities at the Valentine Gold Project (the “Project”) in the central region of Newfoundland and Labrador (“NL”). Second Quarter HighlightsAt June 30, 2022 the Company had cash and cash equivalents of $62 million, leaving it well positioned to execute on its permitting, development, and exploration activities at the Project. Incurred capital expenditures in the quarter were $9.24 million; On May 26, 2022, the Company announced that a draft Environmental Assessment (“EA”) Report had been filed by the Impact Assessment Agency of Canada for the Project. The draft EA Report, and accompanying draft conditions...

Continue reading

XpresSpa Group Announces the Re-Opening of XpresSpa™ Location at John F. Kennedy International Airport’s Terminal 4

Resurgence of Travel Sees Surge in Demand of Airport Self-care Solutions and Amenities for PassengersXpresSpa at JFK Terminal 4 XpresSpa Re-Opening at JFK, Terminal 4 Gate B22.NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) — XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, announced the re-opening of one of its top-performing XpresSpa™ locations at John F. Kennedy (JFK) International Airport’s Terminal 4.   Located in Terminal 4 near Gate B22, the re-opened XpresSpa will meet the needs of a new era of post-pandemic travelers—health-conscious air passengers seeking more self-care solutions and amenities—by providing traditional wellness services, such as neck and back massage, as well as state-of-the-art solutions incorporating technology that gives therapeutic...

Continue reading

Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful completion of pre-BLA meetings in July 2022 Biologics license application (“BLA”) submission for both metastatic and locally advanced cutaneous squamous cell carcinoma on track for later this year WALTHAM, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2022, and recent corporate highlights. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “Over the past few months, we have made substantial progress towards the regulatory submission for, and potential approval...

Continue reading

VYNE Therapeutics Reports Second Quarter 2022 Financial Results

BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022. “We believe our BET inhibitor platform holds unique and significant potential to address several immuno-inflammatory diseases, and we look forward to communicating our future plans following our review of our pipeline and prioritization of activities,” said David Domzalski, President and Chief Executive Officer of VYNE.Financial Performance(in thousands) Three Months Ended June 30,   Six Months Ended June 30,    2022       2021       2022       2021  Loss from continuing...

Continue reading

Copper Lake Resources Announces Closing of First Tranche of Non-Brokered Private Placement

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) — Copper Lake Resources Ltd. (TSX-V: CPL, Frankfurt: WOI, OTC: WTCZF) (“Copper Lake” or the “Company”) is pleased to announce the closing of a first tranche of a private placement of units of the Company (the “Private Placement”) for gross proceeds of $1,346,250. The Private Placement is comprised of the issuance of 8,313,890 Non Flow-Through Units (“NFT Units”) at a price of $0.09 per NFT Unit and 5,980,000 Flow-Through Units (“FT Units”) at a price of $0.10 per FT Unit. Each NFT Unit is comprised of one common share in the capital of Copper Lake (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each FT Unit is comprised of one Flow-Through common share and one-half of one Common Share purchase warrant (each whole warrant a “Warrant”). Each Warrant entitles the holder...

Continue reading

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s Disease and Congenital Adrenal Hyperplasia CRN04777 and CRN04894 Phase 2 Studies Expected to Commence Following Finalization of Study Protocols with Global Regulators SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the second quarter ended June 30, 2022. “Enrollment is on-track in our Phase 3 PATHFNDR program for paltusotine in acromegaly and our Phase 2 study in carcinoid syndrome, with results from these studies expected in 2023,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics....

Continue reading

Applied Blockchain Secures New $15 Million Credit Facility to Refinance Existing Debt and Expand Liquidity Position

DALLAS, Aug. 12, 2022 (GLOBE NEWSWIRE) — Applied Blockchain, Inc. (Nasdaq: APLD) (“Applied Blockchain” or the “Company”) announced today that on July 25, 2022, the Company entered into a loan agreement with a North Dakota-based bank for a credit facility with a maximum principal amount of $15.0 million. The Company intends to use the facility to repay its existing debt and provide additional liquidity to fund the buildout of its datacenters. Applied Blockchain expects the initial interest rate of the Loan to be 1.5% for the first 13 months after taking into account state-based economic incentives and the remainder of the term rate to be 6.5%. “The new credit facility doubles our loan-to-value on our Jamestown facility and provides us with additional capital to fund our growth plans and deliver on the increasing...

Continue reading

Rubicon Technology, Inc. Sets Record Date for its $11.00 per share Cash Distribution

BENSENVILLE, IL., Aug. 12, 2022 (GLOBE NEWSWIRE) — Rubicon Technology, Inc. (Nasdaq: RBCN) (“Rubicon” or the “Company”) announced today that, in connection with the cash tender offer (the “Offer”) by Janel Corporation (“Janel”) for up to 45% of Rubicon’s issued and outstanding common stock, par value $.001 per share (“Common Stock”), the Company’s Board of Directors has set August 23, 2022 (the “Record Date”) as the record date for its cash distribution of $11.00 per share of Common Stock (the “Distribution”). The Distribution and the Record Date are conditioned upon the consummation of the Offer by August 19, 2022. If such condition has occurred it is anticipated that the Distribution will be paid on or about August 29, 2022 (the “Payment Date”). The payment of the Distribution represents more than 25% of the price per share of...

Continue reading

PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) — PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2022. “During the second quarter we completed a successful initial public offering expected to fund operations into the first half of 2025 and initiated our Phase 1 Healthy Normal Volunteer (HNV) clinical trial of PGN-EDO51, our lead program for the treatment of Duchenne muscular dystrophy (DMD) patients who are amenable to an exon 51 skipping therapeutic approach,” stated James McArthur, Ph.D., President and CEO of PepGen. “PepGen looks forward to reporting the initial clinical results from our EDO51 HNV...

Continue reading

InnerScope Hearing Technologies (OTC: INND) Reports Record Revenues for a Profitable Q2 2022

 Financial Highlights:Second Quarter 2022 Consolidated Net Revenues Rose to $6,910,386 from $404,676 Compared to First Quarter 2022 Records $3,881,620 Net Profit for Three Months Ended June 30, 2022 $7,315,062 Year Over Year Revenue Growth for Six Months Ended June 30, 2022, compared to $47,392 for Six Months Ended June 30, 2021 Second Quarter Positive EBT of 56%ROSEVILLE, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) — via InvestorWire — InnerScope Hearing Technologies Inc. (OTC: $INND) (“InnerScope”), an emerging and disruptive leader in the Direct-to-Consumer Hearing Technology space and will be in the upcoming OTC Hearing Aid market, today reported record-setting consolidated net revenues of $6,910,386 for second-quarter ended June 30, 2022, (“Q2 2022”) compared to $404,676 for first-quarter ended...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.